Key Advances in the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorder

Release Date: June 11, 2021 
Last Reviewed: May 27, 2021
Expiration Date: June 11, 2022
Time to Complete Activity:  1.0 hour

*This activity expired for credit on June 11, 2022 and is no longer available for credit

Andrew G. Lee, MD 

Professor of Ophthalmology, Neurology, and Neurosurgery
Weill Cornell Medicine
Chair, Blanton Eye Institute
Houston, TX

Brian Gary Weinshenker, MD, FRCP(C), FAAN
Professor of Neurology and Consultant in Neurology
Mayo Clinic
Rochester, MN
This activity is provided by Paradigm Medical Communications, LLC.   

Disclosure of Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Target Audience
This activity has been designed to address the educational needs of neurologists. It may also benefit neurology nurse practitioners and PAs; ophthalmologists; pharmacists; emergency medicine clinicians; and other healthcare professionals involved in the treatment of patients with neuromyelitis optica spectrum disorder (NMOSD).

Statement of Need
Achieving a quick and correct diagnosis of NMOSD remains challenging, even after the discovery of disease-specific autoantibodies to aquaporin-4 (AQP4). Salient symptoms of NMOSD are non-specific, and some clinicians have confused the condition with multiple sclerosis (MS) or other disorders. Until recently, treatments to manage acute attacks and prevent future episodes were limited to off-label options like azathioprine, mycophenolate, and rituximab. However, within the last 2 years, the therapeutic landscape has widened significantly with FDA approval of eculizumab, inebilizumab, and satralizumab. To improve patient outcomes, neurologists would benefit from continuing education that keeps them up to date on treatment advances and best practices for making a timely, accurate NMOSD diagnosis.  

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify diagnostic clues that facilitate the differentiation of NMOSD from other autoimmune diseases, such as MS
  • Apply evidence-based strategies and clinical guidance to optimize treatment selection for patients with NMOSD
  • Describe the mechanism of action for emerging and newly approved therapies indicate for NMOSD, along with associated safety and efficacy data

Physician Accreditation Statement
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

PA Continuing Education
PAs may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Instructions for Participation 
To receive a CME certificate of participation, you should:

  • Follow instructions to register or log in with your professional information and complete the preactivity assessment
  • View the online activity in its entirety
  • Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest

A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.

For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949 or

There is no fee required for participation in this activity.

Hardware/Software Requirements
This certified CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.

Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+

PDF documents
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here:

Technical Support: If you have any technical problems or playback issues email us at

In accordance with ACCME requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below. Any potential conflicts of interest have been resolved.

Andrew Lee, MD
No financial relationships to disclose.

Brian Gary Weinshenker, MD, FRCP(C), FAAN
Royalty: RSR Limited
Patents/Intellectual Property Rights: NMO-IgG
Consulting Fees: Chugai Pharmaceutical Co., Ltd.; F. Hoffmann-La Roche AG; Genentech, Inc.; Mitsubishi Tanabe Pharma Corporation; UCB, Inc.
Speakers Bureau: Genentech, Inc.; F. Hoffmann-La Roche AG; Novartis
Adjudication Committees: Alexion Pharmaceuticals Inc.; Viela Bio, Inc.

Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.

The independent peer reviewer has no financial relationships to disclose.

Resolution of Conflict of Interest
Paradigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the US Food and Drug Administration (FDA).

This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.

As an ACCME-accredited provider, Paradigm Medical Communications, LLC’s activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC. 

Terms of Use and Privacy Policy
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity.

Privacy policy
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.

Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.

Contact Us
If you have any questions or comments, please email us at

© 2021 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.